One of FDA's current PCB concerns is estimating the biological half-time of the substances in the body, according to Kolbye. If the PCB biological half-time is under one-half year, there probably is not a problem in the U.S., he said. But, Kolbye added, if the PCB half-time is longer, the problem may be "serious."